Drugs for Neglected Diseases initiative

The Drugs for Neglected Diseases initiative (DNDi) is a collaborative, non-profit organization dedicated to developing new treatments for neglected diseases that affect millions of people worldwide. Established in 2003, DNDi aims to address the urgent need for effective and affordable medicines for diseases such as sleeping sickness, leishmaniasis, and Chagas disease.

With a strong commitment to innovation, DNDi works closely with various partners, including academic institutions, pharmaceutical companies, and governments, to accelerate the research and development process. The organization focuses on patient needs and prioritizes diseases that are often overlooked by the pharmaceutical industry due to limited market incentives.

DNDi’s approach is characterized by:

• Collaborative Research: Engaging in partnerships to leverage expertise and resources.
• Patient-Centric Development: Ensuring that the voices of patients are heard in the drug development process.
• Access and Affordability: Striving to make treatments accessible and affordable for those in need.

Headquartered in the UK, DNDi operates globally, with projects in various countries where neglected diseases are prevalent. The organization has successfully brought several new treatments to market, significantly improving the lives of affected populations.

Through its innovative model, DNDi continues to challenge the status quo in drug development, advocating for the rights of patients and the importance of addressing neglected diseases. The vision of DNDi is a world where everyone has access to the medicines they need, regardless of their economic status or geographical location.